New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
While zuranolone may show promise for the treatment of depressive episodes in patients with bipolar disorder, more research is needed.
A study using indirect comparisons suggests that zuranolone is more effective than the SSRIs for the treatment of PPD. Should it be the first choice for treatment?
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
